Go Deep
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 6,910 | -27.5 | 19.04 | 2.96 | 6,060.92 |
| Oct 2026 | 7,286 | -26.6 | 18.43 | 2.96 | 5,814.32 |
| Oct 2026 | 9,298 | -25.5 | 17.64 | 2.96 | 5,535.94 |
| Oct 2026 | 9,249 | -25.6 | 17.71 | 2.96 | 5,542.09 |
| Oct 2026 | 9,222 | -25.5 | 17.75 | 2.96 | 5,555.22 |
| Oct 2026 | 9,754 | -24.5 | 16.96 | 2.96 | 5,294.57 |
| Oct 2026 | 9,482 | -25.1 | 17.36 | 2.96 | 5,426.34 |
| Oct 2026 | 9,136 | -25.8 | 17.88 | 2.96 | 5,586.58 |
| Oct 2026 | 9,153 | -25.8 | 17.85 | 2.96 | 5,565.21 |
| Oct 2026 | 9,251 | -25.6 | 17.71 | 2.96 | 5,508.65 |
Arrowhead Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 75,253,000.0 | 73,737,000.0 | 264,033,000.0 | 256,472,000.0 |
| Net Profit | -194,280,000.0 | -132,732,000.0 | 30,811,000.0 | -23,750,000.0 |
| EPS | -1.4 | -0.9 | 0.2 | — |
Arrowhead Pharmaceuticals, Inc. Revenue & Profit: Last 4 Years
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Revenue | 829,448,000.0 | 3,551,000.0 | 240,735,000.0 | 243,231,000.0 |
| Net Profit | -1,631,000.0 | -599,493,000.0 | -205,275,000.0 | -176,063,000.0 |
| EPS | -0.0 | -5.0 | -1.9 | -1.6 |
Arrowhead Pharmaceuticals, Inc. Balance Sheet
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Total Assets | 1,385,295,000.0 | 1,139,802,000.0 | 765,552,000.0 | 691,939,000.0 |
| Total Liabilities | 881,879,000.0 | 948,739,000.0 | 478,390,000.0 | 273,600,000.0 |
| Total Equity | 466,052,000.0 | 185,444,000.0 | 271,343,000.0 | 398,520,000.0 |
Owes vs Owns
Arrowhead Pharmaceuticals, Inc. owed $0.78 for every $1 it owned in Jun 2026, up from $0.40 in Sep 2022.
| Period | Jun 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.78× | 0.64× | 0.83× | 0.62× | 0.40× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Arrowhead Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Sep 2025
Cash & short-term investments 66.4%Fixed assets (tangible) 30.8%Other assets 1.9%
How it's funded — Sep 2025
Short-term debt 2.9%Long-term debt 15.5%Payables 1.3%Other liabilities 44.0%Shareholders' equity 36.3%
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 919.4 | 681.0 | 403.6 | 376.4 |
| Receivables | 6.8 | 0.0 | 0.0 | 1.4 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 426.4 | 431.3 | 335.6 | 168.6 |
| Intangible assets | 6.9 | 8.6 | 10.3 | 12.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 105.9 |
| Other assets | 25.8 | 19.0 | 16.1 | 27.7 |
| Liabilities & equity | ||||
| Short-term debt | 40.0 | 6.3 | 10.6 | 2.8 |
| Long-term debt | 214.9 | 393.2 | 104.6 | 78.8 |
| Payables | 17.7 | 11.4 | 35.9 | 2.9 |
| Other liabilities | 609.3 | 537.8 | 327.4 | 189.2 |
| Shareholders' equity | 503.4 | 191.1 | 287.2 | 418.3 |
| Net tangible assets | 459.2 | 176.9 | 261.1 | 386.6 |
Arrowhead Pharmaceuticals, Inc. Cash Flow
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Operating Activities | 179,552,000.0 | -462,851,000.0 | -153,890,000.0 | -136,131,000.0 |
| Investing Activities | -129,294,000.0 | -420,072,000.0 | -96,155,000.0 | -5,417,000.0 |
| Financing Activities | 74,006,000.0 | 870,520,000.0 | 253,053,000.0 | 65,186,000.0 |